Evidence map›Paper›PMID 31689825›Full record

ArticleMedicine2019

Polyphyllin I induces cell cycle arrest in prostate cancer cells via the upregulation of IL6 and P21 expression.

Denglu Zhang, Shuai Liu, Zhiyong Liu, Chenchen Ma, Yuehua Jiang, Chao Sun, Kailin Li, Guangshang Cao, Zhaomin Lin, Peng Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The role ofHeliyon · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Denglu ZhangDepartment of Central Research Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
Shuai LiuDepartment of Central Research Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
Zhiyong LiuDepartment of Central Research Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
Chenchen MaDepartment of Central Research Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
Yuehua JiangDepartment of Central Research Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
Chao SunDepartment of Central Research Laboratory, The Second Hospital of Shandong University, Shandong University.
Kailin LiDepartment of Central Research Laboratory, The Second Hospital of Shandong University, Shandong University.
Guangshang CaoDepartment of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
Zhaomin LinDepartment of Central Research Laboratory, The Second Hospital of Shandong University, Shandong University.
Peng WangDepartment of Central Research Laboratory, The Second Hospital of Shandong University, Shandong University.
Jianye ZhangDepartment of Urology, The Second Hospital of Shandong University, Jinan, Shandong, China.
Dawei XuDepartment of Medicine, Division of Hematology and Centre for Molecular Medicine, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.
Feng KongDepartment of Central Research Laboratory, The Second Hospital of Shandong University, Shandong University.
Shengtian ZhaoDepartment of Urology, The Second Hospital of Shandong University, Jinan, Shandong, China.
Affiliated Hospital of Shandong University of Traditional Chinese Medicine · CNSecond Hospital of Shandong University · CNKarolinska Institutet · SEShandong Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolyphyllin I has been reported to possess anticancer properties in various cancer types, including prostate cancer. However, little is known about the potential of Polyphyllin I in induction of prostate cancer cell cycle arrest and its underlying mechanisms.

methodsThe anti-proliferation activity of Polyphyllin I was tested using cell counting kit-8 assay. The cell cycle arrest effects of Polyphyllin I were confirmed by flow cytometry. Western blot was used to test the effect of Polyphyllin I on cell cycle-related protein expression. Reverse transcription-polymerase chain reaction was used to test the expression of genes regulating P21 expression.

resultsPolyphyllin I induced prostate cancer cell cycle arrest in G0/G1 phase in concentration-dependent manner. Polyphyllin I induced cell cycle arrest by upregulating the expression of P21. Further studies showed that the upregulation of p21 expression induced by Polyphyllin I via the upregulation of IL6 expression.

conclusionPolyphyllin I could induce cell cycle arrest in G0/G1 phase in prostate cancer cells by upregulating the expression of P21 and IL6.

Indexed as

Cell Cycle CheckpointsCell Line, TumorCyclin-Dependent Kinase Inhibitor p21DiosgeninHumansInterleukin-6MaleProstatic NeoplasmsUp-RegulationCyclin-Dependent Kinase Inhibitor p21DiosgeninInterleukin-6polyphyllin I

Identifiers

PMID31689825
PMCPMC6946393
OpenAlexW2989455068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.